LV10870B - Novel derivatives of phospholipids - Google Patents

Novel derivatives of phospholipids Download PDF

Info

Publication number: LV10870B
Authority: LV; Latvia
Prior art keywords: compound; treatment; phosphate; mmol; active ingredient
Prior art date: 1992-07-11

Application number

LVP-93-988A

Other languages

English (en)

Latvian (lv)

Other versions

LV10870A (lv

Inventor

Gerhard Noessner

Bernhard Kutscher

Juergen Engel

Wolfgang Schumacher

Jurij Stekar

Peter Hilgard

Original Assignee

Asta Medica Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-11

Filing date

1993-07-12

Publication date

1996-06-20

1993-07-12 Application filed by Asta Medica Ag filed Critical Asta Medica Ag

1995-10-20 Publication of LV10870A publication Critical patent/LV10870A/xx

1996-06-20 Publication of LV10870B publication Critical patent/LV10870B/lv

Links

150000003904 phospholipids Chemical class 0.000 title claims abstract 3
239000003814 drug Substances 0.000 claims abstract 10
238000002360 preparation method Methods 0.000 claims abstract 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 24
150000001875 compounds Chemical class 0.000 claims description 20
238000011282 treatment Methods 0.000 claims description 9
-1 Octadecyl - (1,1 - dimethylpiperidinio - 4 - yl) Chemical group 0.000 claims description 8
238000000034 method Methods 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 4
208000030507 AIDS Diseases 0.000 claims description 3
238000006243 chemical reaction Methods 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
229910052757 nitrogen Chemical group 0.000 claims description 3
239000002904 solvent Substances 0.000 claims description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
239000000203 mixture Substances 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims 7
229910019142 PO4 Inorganic materials 0.000 claims 6
239000010452 phosphate Substances 0.000 claims 6
239000000546 pharmaceutical excipient Substances 0.000 claims 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
210000001185 bone marrow Anatomy 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
239000001257 hydrogen Substances 0.000 claims 2
229910052760 oxygen Inorganic materials 0.000 claims 2
239000001301 oxygen Substances 0.000 claims 2
125000004430 oxygen atom Chemical group O* 0.000 claims 2
FFKIVZSCTWPXNT-UHFFFAOYSA-N 6,6-dimethyl-3-octadecoxy-2,4-dioxa-6-azonia-3$l^{5}-phosphabicyclo[3.3.1]nonane 3-oxide Chemical compound C1C[N+](C)(C)C2OP(OCCCCCCCCCCCCCCCCCC)(=O)OC1C2 FFKIVZSCTWPXNT-UHFFFAOYSA-N 0.000 claims 1
208000023275 Autoimmune disease Diseases 0.000 claims 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
208000004554 Leishmaniasis Diseases 0.000 claims 1
208000031888 Mycoses Diseases 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
230000002378 acidificating effect Effects 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 claims 1
239000002168 alkylating agent Substances 0.000 claims 1
229940100198 alkylating agent Drugs 0.000 claims 1
239000002246 antineoplastic agent Substances 0.000 claims 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
229910052794 bromium Inorganic materials 0.000 claims 1
229910052801 chlorine Inorganic materials 0.000 claims 1
125000004122 cyclic group Chemical group 0.000 claims 1
239000000824 cytostatic agent Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
150000004820 halides Chemical class 0.000 claims 1
150000002500 ions Chemical class 0.000 claims 1
230000003902 lesion Effects 0.000 claims 1
239000012046 mixed solvent Substances 0.000 claims 1
201000006417 multiple sclerosis Diseases 0.000 claims 1
125000004433 nitrogen atom Chemical group N* 0.000 claims 1
239000003960 organic solvent Substances 0.000 claims 1
125000004437 phosphorous atom Chemical group 0.000 claims 1
229910052698 phosphorus Inorganic materials 0.000 claims 1
238000000746 purification Methods 0.000 claims 1
229920006395 saturated elastomer Polymers 0.000 claims 1
208000017520 skin disease Diseases 0.000 claims 1
125000004417 unsaturated alkyl group Chemical group 0.000 claims 1
230000003612 virological effect Effects 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 129
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 67
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 50
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 42
235000019441 ethanol Nutrition 0.000 description 39
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
229960001701 chloroform Drugs 0.000 description 25
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 22
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 21
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 21
229910001868 water Inorganic materials 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
238000000921 elemental analysis Methods 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
239000000243 solution Substances 0.000 description 8
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000012071 phase Substances 0.000 description 5
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
239000001632 sodium acetate Substances 0.000 description 4
235000017281 sodium acetate Nutrition 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
239000000126 substance Substances 0.000 description 3
CFOQKXQWGLAKSK-KTKRTIGZSA-N (13Z)-docosen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCO CFOQKXQWGLAKSK-KTKRTIGZSA-N 0.000 description 2
CFOQKXQWGLAKSK-UHFFFAOYSA-N 13-docosen-1-ol Natural products CCCCCCCCC=CCCCCCCCCCCCCO CFOQKXQWGLAKSK-UHFFFAOYSA-N 0.000 description 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
240000007124 Brassica oleracea Species 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
206010013786 Dry skin Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241001116389 Aloe Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
101100116570 Caenorhabditis elegans cup-2 gene Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
101100116572 Drosophila melanogaster Der-1 gene Proteins 0.000 description 1
101100453960 Drosophila melanogaster klar gene Proteins 0.000 description 1
KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
101100421142 Mus musculus Selenon gene Proteins 0.000 description 1
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
108091006503 SLC26A1 Proteins 0.000 description 1
101100008053 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cut9 gene Proteins 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
MMAKJMJXJYHDDQ-UHFFFAOYSA-N [Cl].CCCCO Chemical compound [Cl].CCCCO MMAKJMJXJYHDDQ-UHFFFAOYSA-N 0.000 description 1
235000013334 alcoholic beverage Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
235000011399 aloe vera Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
239000013078 crystal Substances 0.000 description 1
HJSLFCCWAKVHIW-UHFFFAOYSA-N cyclohexane-1,3-dione Chemical compound O=C1CCCC(=O)C1 HJSLFCCWAKVHIW-UHFFFAOYSA-N 0.000 description 1
238000004821 distillation Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
238000001665 trituration Methods 0.000 description 1
238000003260 vortexing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Physical Education & Sports Medicine (AREA)
AIDS & HIV (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Immunology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Inorganic Compounds Of Heavy Metals (AREA)

LVP-93-988A 1992-07-11 1993-07-12 Novel derivatives of phospholipids LV10870B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4222910A DE4222910A1 (de)	1992-07-11	1992-07-11	Neue Phospholipidderivate

Publications (2)

Publication Number	Publication Date
LV10870A LV10870A (lv)	1995-10-20
LV10870B true LV10870B (en)	1996-06-20

Family

ID=6463031

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-93-988A LV10870B (en)	1992-07-11	1993-07-12	Novel derivatives of phospholipids

Country Status (31)

Country	Link
EP (1)	EP0579939B1 (da)
JP (1)	JP3311431B2 (da)
KR (1)	KR100297180B1 (da)
CN (1)	CN1039012C (da)
AT (1)	ATE176477T1 (da)
AU (1)	AU664101B2 (da)
BR (1)	BR9302809A (da)
CA (2)	CA2100228C (da)
CZ (1)	CZ290863B6 (da)
DE (2)	DE4222910A1 (da)
DK (1)	DK0579939T3 (da)
EE (1)	EE03140B1 (da)
ES (1)	ES2129053T3 (da)
FI (1)	FI111262B (da)
GR (1)	GR3029602T3 (da)
HR (1)	HRP931046B1 (da)
HU (1)	HU218783B (da)
IL (1)	IL106289A (da)
LT (1)	LT3113B (da)
LV (1)	LV10870B (da)
MX (1)	MX9304133A (da)
NO (1)	NO306468B1 (da)
PL (3)	PL177811B1 (da)
RU (1)	RU2108336C1 (da)
SG (1)	SG46249A1 (da)
SI (1)	SI9300365B (da)
SK (1)	SK283827B6 (da)
TW (1)	TW304956B (da)
UA (1)	UA40567C2 (da)
YU (1)	YU49079B (da)
ZA (1)	ZA934971B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101146532B (zh)	2005-01-21	2012-05-09	阿斯泰克斯治疗有限公司	药物化合物
EP1800684A1 (en) *	2005-12-20	2007-06-27	Zentaris GmbH	Novel alkyl phospholipid derivatives and uses thereof
PL1962862T3 (pl) *	2005-12-19	2014-01-31	Aeterna Zentaris Gmbh	Pochodne alkilofosfolipidów o ograniczonej cytotoksyczności i ich zastosowania
EP1869981A1 (de) *	2006-06-21	2007-12-26	Staatliches Weinbauinstitut Freiburg	Alkylphospholipide und Lyso-Phospholipide zur Bekämpfung von Pflanzenpathogenen
EP2073807A1 (en)	2006-10-12	2009-07-01	Astex Therapeutics Limited	Pharmaceutical combinations
US8916552B2 (en)	2006-10-12	2014-12-23	Astex Therapeutics Limited	Pharmaceutical combinations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3164332D1 (en) *	1980-10-21	1984-07-26	Boehringer Mannheim Gmbh	Phospholipids that contain sulphur, process for their preparation and medicines containing these compounds
JPS5984824A (ja) *	1982-11-08	1984-05-16	Takeda Chem Ind Ltd	抗腫瘍剤
DE3530767A1 (de) *	1985-08-28	1987-03-12	Max Planck Gesellschaft	Mittel gegen multiple sklerose
IE59777B1 (en) *	1985-12-04	1994-04-06	Max Planck Gesellschaft	Medicaments
EP0257762B1 (en) *	1986-07-14	1990-10-10	Nippon Chemiphar Co., Ltd.	Novel glycerol derivative and anti-hypertensive agent
DE3881925T2 (de) *	1987-03-24	1994-01-27	Nippon Chemiphar Co	Glycerol-Derivate und anti-hypertensives Mittel.
DE3906952A1 (de) *	1989-03-04	1990-09-06	Boehringer Mannheim Gmbh	(3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel
DE3942933A1 (de) *	1989-12-23	1991-06-27	Boehringer Mannheim Gmbh	Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate
DE4114586A1 (de) *	1991-05-04	1992-11-05	Boehringer Mannheim Gmbh	Arzneimittel enthaltend azacyclodiphosphonsaeurederivate, neue azacyclodiphosphonsaeurederivate sowie verfahren zu deren herstellung

1992
- 1992-07-11 DE DE4222910A patent/DE4222910A1/de not_active Ceased
1993
- 1993-06-01 TW TW082104345A patent/TW304956B/zh not_active IP Right Cessation
- 1993-06-03 EP EP93108904A patent/EP0579939B1/de not_active Expired - Lifetime
- 1993-06-03 AT AT93108904T patent/ATE176477T1/de active
- 1993-06-03 DK DK93108904T patent/DK0579939T3/da active
- 1993-06-03 SG SG1996001626A patent/SG46249A1/en unknown
- 1993-06-03 DE DE59309355T patent/DE59309355D1/de not_active Expired - Lifetime
- 1993-06-03 ES ES93108904T patent/ES2129053T3/es not_active Expired - Lifetime
- 1993-06-04 LT LTIP620A patent/LT3113B/lt not_active IP Right Cessation
- 1993-06-23 CZ CZ19931249A patent/CZ290863B6/cs not_active IP Right Cessation
- 1993-06-28 SK SK670-93A patent/SK283827B6/sk not_active IP Right Cessation
- 1993-07-06 YU YU47393A patent/YU49079B/sh unknown
- 1993-07-08 PL PL93318679A patent/PL177811B1/pl unknown
- 1993-07-08 JP JP16911493A patent/JP3311431B2/ja not_active Expired - Lifetime
- 1993-07-08 PL PL93318680A patent/PL175607B1/pl unknown
- 1993-07-08 PL PL93299624A patent/PL173388B1/pl unknown
- 1993-07-08 NO NO932502A patent/NO306468B1/no not_active IP Right Cessation
- 1993-07-09 ZA ZA934971A patent/ZA934971B/xx unknown
- 1993-07-09 UA UA93002052A patent/UA40567C2/uk unknown
- 1993-07-09 CA CA002100228A patent/CA2100228C/en not_active Expired - Lifetime
- 1993-07-09 IL IL10628993A patent/IL106289A/xx not_active IP Right Cessation
- 1993-07-09 BR BR9302809A patent/BR9302809A/pt not_active Application Discontinuation
- 1993-07-09 HR HR931046A patent/HRP931046B1/xx not_active IP Right Cessation
- 1993-07-09 HU HU9301992A patent/HU218783B/hu unknown
- 1993-07-09 AU AU41864/93A patent/AU664101B2/en not_active Expired
- 1993-07-09 MX MX9304133A patent/MX9304133A/es active IP Right Grant
- 1993-07-09 FI FI933165A patent/FI111262B/fi not_active IP Right Cessation
- 1993-07-09 SI SI9300365A patent/SI9300365B/sl unknown
- 1993-07-09 RU RU93047049A patent/RU2108336C1/ru active
- 1993-07-09 CA CA002511753A patent/CA2511753C/en not_active Expired - Lifetime
- 1993-07-10 KR KR1019930012980A patent/KR100297180B1/ko not_active IP Right Cessation
- 1993-07-10 CN CN93108564A patent/CN1039012C/zh not_active Expired - Lifetime
- 1993-07-12 LV LVP-93-988A patent/LV10870B/lv unknown
1994
- 1994-10-25 EE EE9400199A patent/EE03140B1/xx unknown
1999
- 1999-03-08 GR GR990400689T patent/GR3029602T3/el unknown

Also Published As

Publication number	Publication date
JP3311431B2 (ja)	2002-08-05
YU47393A (sh)	1997-08-22
EP0579939B1 (de)	1999-02-03
CZ290863B6 (cs)	2002-11-13
CA2100228A1 (en)	1994-01-12
LTIP620A (en)	1994-07-15
ZA934971B (en)	1994-02-01
UA40567C2 (uk)	2001-08-15
SI9300365B (sl)	2002-02-28
SG46249A1 (en)	1998-02-20
DE4222910A1 (de)	1994-01-13
RU2108336C1 (ru)	1998-04-10
PL173388B1 (pl)	1998-02-27
FI933165A (fi)	1994-01-12
HRP931046A2 (en)	1997-04-30
BR9302809A (pt)	1994-03-15
CA2511753C (en)	2007-09-25
PL177811B1 (pl)	2000-01-31
NO306468B1 (no)	1999-11-08
GR3029602T3 (en)	1999-06-30
MX9304133A (es)	1994-04-29
FI933165A0 (fi)	1993-07-09
YU49079B (sh)	2003-08-29
DE59309355D1 (de)	1999-03-18
EP0579939A1 (de)	1994-01-26
DK0579939T3 (da)	1999-09-20
SI9300365A (en)	1994-03-31
CN1039012C (zh)	1998-07-08
AU4186493A (en)	1994-01-13
ES2129053T3 (es)	1999-06-01
PL175607B1 (pl)	1999-01-29
JPH0733791A (ja)	1995-02-03
CA2511753A1 (en)	1994-01-12
CA2100228C (en)	2006-01-24
NO932502L (no)	1994-01-12
EE03140B1 (et)	1998-12-15
CN1084175A (zh)	1994-03-23
SK283827B6 (sk)	2004-02-03
KR940002265A (ko)	1994-02-17
HU218783B (hu)	2000-12-28
LT3113B (en)	1994-12-27
IL106289A0 (en)	1994-04-12
KR100297180B1 (ko)	2001-11-30
ATE176477T1 (de)	1999-02-15
FI111262B (fi)	2003-06-30
SK67093A3 (en)	1995-03-08
HU9301992D0 (en)	1993-09-28
TW304956B (da)	1997-05-11
AU664101B2 (en)	1995-11-02
HRP931046B1 (en)	2000-06-30
LV10870A (lv)	1995-10-20
NO932502D0 (no)	1993-07-08
PL299624A1 (en)	1994-02-21
CZ124993A3 (en)	1995-03-15
HUT64548A (en)	1994-01-28
IL106289A (en)	2000-06-01

Publication	Publication Date	Title
AT398974B (de)	1995-02-27	Epipodophyllotoxinglucosid-4'-phosphat-derivate deren herstellung, sowie pharmazeutische zusammensetzungen hierzu
EP0248062B1 (de)	1992-05-06	Arzeimittel
EP0303186A2 (de)	1989-02-15	Arylphosphorderivate, ihre Herstellung und Verwendung
DE4141928A1 (de)	1993-06-24	Neue phosphonobernsteinsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3141586C2 (da)	1991-02-21
EP0082364B1 (de)	1986-04-23	(+)-2-(1-(2,6-Dichlorphenoxy)-ethy1)-1,3-diazacyclopent-2-en, dessen Herstellung und seine Verwendung in pharmazeutischen Präparaten
DE3319992A1 (de)	1983-12-08	Amidinverbindungen, verfahren zu ihrer herstellung und pharmazeutische mittel
DE2854308A1 (de)	1979-06-21	Anticholinergische substanzen mit antisekretorischer wirkung, ihre herstellung und verwendung
LV10870B (en)	1996-06-20	Novel derivatives of phospholipids
WO1984000367A1 (en)	1984-02-02	New glycerine derivatives for the synthesis of phospholipides
EP0046961A1 (de)	1982-03-10	Epoxi-cycloalkylalkancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung sowie sie enthaltende Arzneimittel
EP0037934A2 (de)	1981-10-21	Substituierte alpha-Aminocarbonyl-1-benzyl-3,4-dihydro-isochinoline, Verfahren zu deren Herstellung und deren Verwendung
EP0225522A1 (de)	1987-06-16	Imidazopyridazinalkensäureamide, Verfahren ihrer Herstellung, Zwischenprodukte zu ihrer Herstellung
EP0180115A2 (de)	1986-05-07	1,2,4-Triazolo-carbamate und ihre Säureadditionssalze, Verfahren zu ihrer Herstellung und Arzneimittel
EP0534904A1 (de)	1993-03-31	Imidazolylmethyl-Pyridine
EP0521353A1 (de)	1993-01-07	Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung
DE60116081T2 (de)	2006-08-03	Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidate als antitumor-mittel
DD234017A5 (de)	1986-03-19	Verfahre zur herstellung von oxazaphosphorin-derivaten
EP0725061B1 (de)	2000-06-07	Substituierte Indol-Derivate
EP0266308A1 (de)	1988-05-04	Indolo-pyrazino-benzodiazepin-Derivate
DE2336671A1 (de)	1974-01-31	Oxyessigsaeureaether von o-thymotinsaeureestern
DD258415A5 (de)	1988-07-20	Verfahren zur herstellung von phoshonylhydroxyacylprolinen
DE2609862A1 (de)	1976-10-07	Verbindungen mit antidepressiver wirkung
AT393505B (de)	1991-11-11	Arzneimittel, welche alkylphosphoamine in kombination mit einem alkylglycerin enthalten
EP0594999B1 (de)	1998-12-02	Phospholipidderivate, die höhere Elemente der V. Hauptgruppe enthalten